Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment

References

• Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry50(11), 884–897 (2001).
   PubMed Web of Science ®Google Scholar
• Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry163(3), 418–425 (2006).
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med.2(5), e141 (2005).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. In: Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition. American Psychiatric Publishing Inc., Arlington, VA, USA, 565–746 (2006).
   Google Scholar
• Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: relapse rates after 1 year. Am. J. Psychiatry143(9), 1155–1158 (1986).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Treatment of patients with schizophrenia. In: Practice Guidelines for the Treatment of Psychiatric Disorders. American Psychiatric Association, Arlington, VA, USA, 249–440 (2004).
   Google Scholar
• Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs25(2), 109–127 (2011).
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373(9657), 31–41 (2009).
   PubMed Web of Science ®Google Scholar
• Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin–dopamine hypothesis. Prog. Brain Res.172, 199–212 (2008).
   PubMed Web of Science ®Google Scholar
• Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology28(Suppl. 1), 9–26 (2003).
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry156(11), 1686–1696 (1999).
   PubMed Web of Science ®Google Scholar
• Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry35(2), 490–496 (2011).
   PubMed Web of Science ®Google Scholar
• Pae CU, Sohi MS, Seo HJ et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry34(7), 1165–1173 (2010).
   PubMed Web of Science ®Google Scholar
• Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin. Drug Saf.8(3), 373–386 (2009).
   PubMed Web of Science ®Google Scholar
• Pae CU. Pravastatin as a therapeutic agent for atypical antipsychotic-induced metabolic syndrome in patients with schizophrenia. CNS Spectr.13(5), E1 (2008).
   PubMedGoogle Scholar
• Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J. Clin. Psychiatr.59(Suppl. 12), 17–22 (1998).
   PubMedGoogle Scholar
• Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog. Neuropsychopharmacol. Biol. Psychiatry28(8), 1213–1219 (2004).
   PubMed Web of Science ®Google Scholar
• Green B. Focus on aripiprazole. Curr. Med. Res. Opin.20(2), 207–213 (2004).
   PubMed Web of Science ®Google Scholar
• Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs22(5), 367–388 (2008).
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology28(8), 1400–1411 (2003).
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther.26(5), 649–666 (2004).
   PubMed Web of Science ®Google Scholar
• Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch. Gen. Psychiatry60(10), 974–977 (2003).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J. Clin. Psychiatr.62(12), 923–924 (2001).
   PubMed Web of Science ®Google Scholar
• Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry164(9), 1411–1417 (2007).
   PubMed Web of Science ®Google Scholar
• Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology32(1), 67–77 (2007).
   PubMed Web of Science ®Google Scholar
• Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208–912. Eur. J. Pharmacol.574(2–3), 103–111 (2007).
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther.302(1), 381–389 (2002).
   PubMed Web of Science ®Google Scholar
• Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann. Pharmacother.37(5), 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• Nahata T, Saini TR. Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J. Pharm. Sci. Technol.63(2), 113–122 (2009).
   PubMedGoogle Scholar
• Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs64(15), 1715–1736 (2004).
   PubMed Web of Science ®Google Scholar
• Abilify®(aripiprazole) prescribing information. Otsuka America Pharmaceutical Inc, Rockville, MD, USA.
   Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol.44(2), 179–187 (2004).
   PubMed Web of Science ®Google Scholar
• Kinghorn WA, McEvoy JP. Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert Rev. Neurother.5(3), 297–307 (2005).
   PubMedGoogle Scholar
• Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther. Drug Monit.28(6), 744–749 (2006).
   PubMed Web of Science ®Google Scholar
• Findling RL, Robb A, Nyilas M et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J. Psychiatry165(11), 1432–1441 (2008).
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatr.63(9), 763–771 (2002).
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res.61(2–3), 123–136 (2003).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry60(7), 681–690 (2003).
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol.6(4), 325–337 (2003).
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatr.64(9), 1048–1056 (2003).
   PubMed Web of Science ®Google Scholar
• Kane JM, Crandall DT, Marcus RN et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr. Res.95(1–3), 143–150 (2007).
   PubMed Web of Science ®Google Scholar
• Kerwin R, Millet B, Herman E et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur. Psychiatry22(7), 433–443 (2007).
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol. Psychiatry65(6), 510–517 (2009).
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatr.65(Suppl. 18), 47–56 (2004).
   PubMed Web of Science ®Google Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl.)189(2), 259–266 (2006).
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J. Clin. Psychiatr.70(10), 1348–1357 (2009).
   PubMed Web of Science ®Google Scholar
• Horacek J, Bubenikova-Valesova V, Kopecek M et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs20(5), 389–409 (2006).
   PubMed Web of Science ®Google Scholar
• Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs22(4), 335–352 (2008).
   PubMed Web of Science ®Google Scholar
• Grunder G, Kungel M, Ebrecht M, Gorocs T, Modell S. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry39(Suppl. 1), S21–S25 (2006).
   PubMedGoogle Scholar
• Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann. Pharmacother.40(3), 575 (2006).
   PubMed Web of Science ®Google Scholar
• Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch. Womens Ment. Health11(3), 249–250 (2008).
   PubMed Web of Science ®Google Scholar
• Salzman C, Jeste DV, Meyer RE et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J. Clin. Psychiatr.69(6), 889–898 (2008).
   PubMed Web of Science ®Google Scholar
• De Deyn P, Jeste DV, Swanink R et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled study. J. Clin. Psychopharmacol.25(5), 463–467 (2005).
   PubMed Web of Science ®Google Scholar
• Mintzer JE, Tune LE, Breder CD et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am. J. Geriatr. Psychiatry15(11), 918–931 (2007).
   PubMed Web of Science ®Google Scholar
• Streim JE, Porsteinsson AP, Breder CD et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am. J. Geriatr. Psychiatry16(7), 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Battaglia J. Pharmacological management of acute agitation. Drugs65(9), 1207–1222 (2005).
   PubMed Web of Science ®Google Scholar
• Andrezina R, Marcus RN, Oren DA et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr. Med. Res. Opin.22(11), 2209–2219 (2006).
   PubMed Web of Science ®Google Scholar
• Andrezina R, Josiassen RC, Marcus RN et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl.)188(3), 281–292 (2006).
   PubMed Web of Science ®Google Scholar
• Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatr.68(1), 111–119 (2007).
   PubMed Web of Science ®Google Scholar
• Rappaport SA, Marcus RN, Manos G, McQuade RD, Oren DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia. J. Am. Med. Dir. Assoc.10(1), 21–27 (2009).
   PubMed Web of Science ®Google Scholar
• Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J. Clin. Psychiatr.68(12), 1876–1885 (2007).
   PubMed Web of Science ®Google Scholar
• Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry59(5), 441–448 (2002).
   PubMed Web of Science ®Google Scholar
• Wright P, Birkett M, David SR et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry158(7), 1149–1151 (2001).
   PubMed Web of Science ®Google Scholar
• Meehan K, Zhang F, David S et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol.21(4), 389–397 (2001).
   PubMed Web of Science ®Google Scholar
• Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl.)155(2), 128–134 (2001).
   PubMed Web of Science ®Google Scholar
• Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J. Clin. Psychiatr.62(1), 12–18 (2001).
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Kane JM, Sancez R et al. Pharmacokinetic study of once-monthly aripiprazole intramuscular patients with schizophrenia. Presented at: 164th Annual Meeting of the American Psychiatric Association. Honolulu, Hawaii, USA, May 14–16 2011.
   Google Scholar
• Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry168(6), 603–609 (2011).
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull.21(3), 419–429 (1995).
   PubMed Web of Science ®Google Scholar
• Narasimhan M, Pae CU, Masand N, Masand P. Partial compliance with antipsychotics and its impact on patient outcomes. Int. J.Psychiatry Clin. Prac.11(2), 102–111 (2007).
   PubMed Web of Science ®Google Scholar
• Weldon PAZ. Medication noncompliance in schizophrenia: Part I. Assessment. J. Pract. Psych. Behav. Health3, 106–110 (1997).
   Google Scholar
• Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J. Clin. Psychiatr.45(5 Pt 2), 50–59 (1984).
   PubMed Web of Science ®Google Scholar